How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

898 results for

Migraine Headache Prophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Migraine headache in adults

Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Migraine headache in adults Last reviewed: February 2019 Last updated: October 2018 Summary Migraine is a chronic, genetically determined, episodic, neurological disorder that usually presents in early-to-mid life. Patients complain of intermittent headache and associated symptoms, such as visual disturbance (...) , nausea, vomiting, and sensitivity to light or noise (photophobia and phonophobia). The diagnosis is based on history and physical examination. No laboratory or imaging tests are essential for diagnosis. Treatment approaches involve identification and avoidance of trigger factors, and the use of medication to treat the acute attack or prevent future attacks. There are no clinical trials that identify one migraine therapy (acute therapy or prophylaxis therapy) as superior over others. Triptans

2018 BMJ Best Practice

2. Migraine headache in adults

Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Migraine headache in adults Last reviewed: February 2019 Last updated: October 2018 Summary Migraine is a chronic, genetically determined, episodic, neurological disorder that usually presents in early-to-mid life. Patients complain of intermittent headache and associated symptoms, such as visual disturbance (...) , nausea, vomiting, and sensitivity to light or noise (photophobia and phonophobia). The diagnosis is based on history and physical examination. No laboratory or imaging tests are essential for diagnosis. Treatment approaches involve identification and avoidance of trigger factors, and the use of medication to treat the acute attack or prevent future attacks. There are no clinical trials that identify one migraine therapy (acute therapy or prophylaxis therapy) as superior over others. Triptans

2018 BMJ Best Practice

3. Migraine and Tension Headache

Migraine and Tension Headache ? 2018 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Migraine and Tension Headache Guideline Background 2 Diagnosis Red flag warning signs 2 Differential diagnosis 2 Imaging 3 Migraine versus tension headache 3 Medication overuse headache 3 Menstruation-related migraine 3 Tension Headache Acute treatment 4 Prophylaxis 5 Migraine Headache Acute treatment 6 Treatment of refractory migraine 7 Prophylaxis 8 Menstruation-related migraine (...) headache medications that the patient has been taking. 2. Stop all acute headache medications. Tapering may be required. 3. Start a prophylactic medication at the same time or, ideally, prior to stopping acute headache medications. See “Options for migraine prophylaxis,” p. 8. 4. Treat symptoms during withdrawal of acute headache medications. 5. Use the SmartPhrase .AVSHEADACHEMEDOVERUSE to develop a written headache treatment plan that includes acute and prophylactic treatment as well as a plan

2018 Kaiser Permanente Clinical Guidelines

4. Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines

Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines (Migauric) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03036761 Recruitment Status

2017 Clinical Trials

5. The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK

The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD Record Status This is a critical abstract (...) treatment; three frequencies of headache, classified as episodic migraine; and three frequencies, classified as chronic migraine. The authors stated that the perspective was that of the UK NHS. Effectiveness data: The main effectiveness data were the probabilities of transition between each health state every 12 weeks. These data were from two randomised controlled trials, within the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) programme. They were multicentre trials of 1,384

2013 NHS Economic Evaluation Database.

6. Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine

Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine 1/5 Public Summary Document Application No. 1168 – Botulinum toxin type A for the prophylaxis of headaches in patients with chronic migraine Sponsor/Applicant/s: Allergan Australia Pty Ltd Date of MSAC consideration: 1 August 2013 1. Purpose of application In February 2011, an application to the Medical Services Advisory Committee (MSAC) was received from Allergan Australia Pty Ltd for injection (...) of botulinum toxin type A (BOTOX ® ) for the prevention (prophylaxis) of chronic migraine. The MSAC application was co-dependent on an application to the Pharmaceutical Benefits Advisory Committee (PBAC) for the drug component of the service (i.e. extension of the current Botulinum Toxin Program (Section 100 arrangements) so the drug is listed for prophylaxis of headaches in adults with chronic migraine who meet certain criteria). The application was lodged during transitional arrangements for managing co

2013 Medical Services Advisory Committee

7. Erenumab (Aimovig) - for the prophylaxis of migraine

nociceptive signalling) and a vasodilator associated with migraine pathophysiology. CGRP levels have been shown to increase significantly during migraine and return to normal with headache relief. 1, 2 Erenumab is licensed for the prophylaxis of migraine in adults who have at least four migraine days per month. 1 The submitting company has requested that SMC considers erenumab for the treatment of adult patients with migraine who have at least four migraine days per month and for whom at least three prior (...) prophylactic treatments have failed. The evidence to support the use of erenumab for the prophylaxis of migraine is based on four clinical studies (STRIVE, ARISE, LIBERTY and Study 295). 3-6 All were randomised, double-blind studies which compared erenumab with placebo over a 12-week double-blind treatment period (24 weeks in STRIVE). STRIVE, ARISE and LIBERTY were phase III study in patients with episodic migraine (defined as =4 to <15 migraine days per month and <15 headache days [migraine and non

2019 Scottish Medicines Consortium

8. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation (PubMed)

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in the main European Guidelines. Previous (2014) European recommendations on limiting the use (...) , with the active participation of the European Headache Federation, concluded that not enough has been done to mitigate the risks associated with in utero exposure to valproate. The review called for more extensive restrictions to the conditions for prescribing, better public awareness, and a more effective education campaign in migrainous women.

Full Text available with Trip Pro

2018 The journal of headache and pain

9. Monoclonal antibodies to prevent migraine headaches

recurrent attacks may benefit from prophylactic therapy. 26 Botulinum toxin has received regulatory approval for the prevention of chronic migraine headaches. This medication requires multiple injections into specific head and neck sites. 1,6,24 Topiramate is used for the prophylaxis of migraine headaches in adults experiencing four or more migraine attacks per month. 27 Other drugs used for migraine prevention are anti-epileptics (divalproex sodium, lamotrigine, gabapentin), antidepressants (...) Monoclonal antibodies to prevent migraine headaches Monoclonal antibodies to prevent migraine headaches | CADTH.ca CADTH Document Viewer Monoclonal antibodies to prevent migraine headaches Table of Contents Search this document Monoclonal antibodies to prevent migraine headaches February 2018 Summary Migraine is a common, chronic, neurological disorder. To prevent chronic migraine headaches, botulinum toxin has received regulatory approval. This medication requires multiple injections

2018 CADTH - Issues in Emerging Health Technologies

10. The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis

The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis By in , , Journal reference: Gaul C, Diener HC, Danesch U, Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516. Link: Published: April 2015 Evidence cookie says… The evidence for combination magnesium, riboflavin, and CoQ10 is at best equivocal for migraine (...) migraine. Cephalalgia 2011 Feb;31(3):357-67. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine–a double-blind placebo-controlled study. Cephalalgia 1996 Oct;16(6):436-40. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003 Jun;43(6):601-10. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin

Full Text available with Trip Pro

2018 Morsels of Evidence

11. The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis

19 2018 The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis By in , , 19 October 2018 Journal reference: Gaul C, Diener HC, Danesch U, Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516. Link: Published: April 2015 Evidence cookie says… The evidence for combination magnesium, riboflavin, and CoQ10 (...) (HIT-6) across episodic and chronic migraine. Cephalalgia 2011 Feb;31(3):357-67. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine–a double-blind placebo-controlled study. Cephalalgia 1996 Oct;16(6):436-40. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003 Jun;43(6):601-10. Maizels M, Blumenfeld

2018 Morsels of Evidence

12. Chronic migraine and chronic tension-type headache

is not a covered benefit. HTCC reimbursement determination: Limitations of coverage: For treatment of chronic migraine (as defined by the International Headache Society), OnabotulinumtoxinA is covered when the following criteria are met: 1) Has not responded to at least three prior pharmacological prophylaxis therapies from two different classes of drugs AND 2) Condition is appropriately managed for medication overuse OnabotulinumtoxinA injections must be discontinued when the condition has shown inadequate (...) with chronic migraine (defined as headaches on =15 days per month of which =8 days are with migraine) if: 1) They have not responded to at least three prior pharmacological prophylaxis therapies from two different classes of drugs AND 2) Their condition is appropriately managed for medication overuse OnabotulinumtoxinA injections must be discontinued in people whose condition: 1) Has shown inadequate response to treatment (defined as <50% reduction in headache days per month after two treatment cycles

2017 Washington Health Care Authority

13. Prophylaxis of migraine headaches with riboflavin: A systematic review. (PubMed)

Prophylaxis of migraine headaches with riboflavin: A systematic review. Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year. Riboflavin has been advocated as a safe, effective prophylactic therapy for the prevention of migraines. The purpose of this study was to provide a systematic review of the current role of riboflavin in the prophylaxis of migraine headache.A MEDLINE literature search inclusive of the dates 1966 (...) articles, and supporting pharmacokinetic and pharmacogenomic data assessing the efficacy and mechanism of riboflavin therapy in the prophylactic treatment of migraine headache.A total of 11 clinical trials reveal a mixed effect of riboflavin in the prophylaxis of migraine headache. Five clinical trials show a consistent positive therapeutic effect in adults; four clinical trials show a mixed effect in paediatric and adolescent patients, and two clinical trials of combination therapy have not shown

Full Text available with Trip Pro

2017 Journal of clinical pharmacy and therapeutics

14. Levetiracetam in compare to Sodium Valproate for prophylaxis in Chronic Migraine Headache: A Randomized Double-blind Clinical Trial. (PubMed)

Levetiracetam in compare to Sodium Valproate for prophylaxis in Chronic Migraine Headache: A Randomized Double-blind Clinical Trial. Migraine is not curable, but preventive treatments are usually used to decrease the intensity and frequency of headache attacks. Different therapeutic options are widely studied for chronic migraine (CM), but all of them have different inefficacies.The aim of this study was to compare the efficacy of levetiracetam versus sodium valproate in the treatment of CM.A (...) ).According to our findings, levetiracetam offered improvement in headache frequency, severity, and MIDAS score in patients with CM. However, levetiracetam was not effective enough for chronic migraine as valproate, despite some significant effect. Thus levetiracetam can be one of the choices for limited chronic migraine subjects who are in contraindication of Valproate.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

2017 Current clinical pharmacology

15. Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03193359 Recruitment Status : Withdrawn (Corporate Decision

2017 Clinical Trials

16. BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine

BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03193346 Recruitment Status : Withdrawn (Corporation Decision) First Posted : June 20, 2017 Last Update

2017 Clinical Trials

17. Randomised controlled trial: Acupuncture prophylaxis of migraine no better than sham acupuncture for decreasing frequency of headaches

Randomised controlled trial: Acupuncture prophylaxis of migraine no better than sham acupuncture for decreasing frequency of headaches Acupuncture prophylaxis of migraine no better than sham acupuncture for decreasing frequency of headaches | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Acupuncture prophylaxis of migraine no better than sham acupuncture for decreasing frequency of headaches Article Text Therapeutics Randomised controlled

2013 Evidence-Based Medicine (Requires free registration)

18. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine

Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Medical Services Advisory Committee. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1168. 2012 Authors' conclusions After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of injecting botulinum toxin type A (Botox®) in refractory chronic migraine, MSAC supports its public funding via a new

2012 Health Technology Assessment (HTA) Database.

19. Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists. (PubMed)

compared to non-headache specialists who prescribed them in 28.7% (96/334) of cases (P < .001). Of the children with chronic migraine, the headache specialist evaluated 135 patients while the non-headache specialists treated 334 children. Non-headache specialists prescribed prophylaxis in the form of natural supplements more frequently (63.8% of cases) compared to the headache specialist (38.5% of children) (P < .001). Moreover, prophylaxis with prescription drugs was utilized more often by headache (...) Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists. This study aims to compare the management practices of a headache specialist with non-headache specialists in the treatment of children with migraine. The use of appropriate rescue medications and prophylactic agents, application of neuroimaging, and short-term outcomes are compared in children treated by the two groups of physicians.A retrospective cohort study was conducted by utilizing the electronic medical

2019 Headache

20. Riboflavin for Migraine Prophylaxis: Something "2-B" excited about?

(with carotene) (42 children) 4 and 200 mg versus identical placebo (48 children): 5 ? No difference in days with migraine or headache intensity. 4,5 ? =50% reduction in frequency: 44% versus 67% (placebo); NSS. 5 ? Limitations: Underpowered 5 o Third study uninterpretable due to significant differences in baseline characteristics. 6 • Systematic reviews did not complete meta-analyses (so we focused on RCTs above). 7-10 Context: • Prophylaxis is recommended for those with =3 moderate-severe headaches/month (...) Riboflavin for Migraine Prophylaxis: Something "2-B" excited about? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca

2017 Tools for Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>